FRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTC-BB:ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and wound clinics. This segment represents its third targeted selling channel and is expected to expand upon the Company’s first two selling channels: government facilities and non-government hospital operating rooms, which are currently supported by Lovell Government Services and Centurion Therapeutics, respectively.
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/The%20logo%20for%20The%20Trade%20Desk%20displayed%20on%20a%20smartphone%20screen%20by%20Mamun_Sheikh%20via%20Shutterstock.jpg)